Four months after CEO's death, biotech company names Lilly vet as leader

Enrique Conterno, a 27-year veteran of Eli Lilly and Co., was named Monday as the new CEO of FibroGen Inc., stepping into a role vacated with the death of founder, chairman and CEO Thomas Neff on Aug. 25. The 64-year-old Neff died unexpectedly after the 500-employee San Francisco company he founded in 1993 won its first regulatory approval, for the drug roxadustat, in China. The company also lined up approvals in Japan, Europe and the United States to treat anemia in chronic kidney disease patients ;…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news